SEASUN BIOMATERIALS, Passed KOSDAQ Technology Special Listing
2022.03.02.
Seasun Biomaterials(CEO Park Hee-kyung), a company specializing in genome-based molecular diagnostics, announced on the 2nd that it had passed the technology evaluation conducted by the Korea Health Industry Promotion Agency and Korea Enterprise Data, a technical evaluation agency designated by the Korea Exchange.
This technology evaluation is the first gateway for special listing on the KOSDAQ technology evaluation, and it is a system that selects promising technology companies with excellent technology by evaluating 35 items such as technology, business feasibility, and growth potential. The technical evaluation is conducted at two specialized evaluation institutions designated by the Korea Exchange. If the evaluation level is A and BBB or higher, a request for preliminary examination for listing is possible.
With the passing of this technology evaluation, Seasun Biomaterials has become eligible to request a preliminary examination for listing on the KOSDAQ. Accordingly, in the first half of this year, the Korea Exchange will request a preliminary examination for listing on the KOSDAQ and go public within the year. The listing organizers are Mirae Asset Securities and Hanhwa Investment & Securities.
Seasun Biomaterials is a company that possesses genomic analysis technology based on functional nucleic acid materials. The main core pipelines include non-invasive prenatal fetal genetic abnormality diagnosis technology, multiple genetic mutation diagnosis technology related to congenital diseases, and epigenetic genome analysis technology closely related to cancer. In particular, in the case of epigenetic genome analysis technology, based on independently developed functional nucleic acids, early cancer diagnosis and monitoring panels have been developed and commercialized to be widely applied to health examinations.
CEO Park Hee-kyung said, “Seasun Bio passed the evaluation with excellent results on the first challenge amid the recent strengthening of technology evaluation standards for bio companies.”adding, “We will push ahead with the listiong schcedule as planned. We promise to prove our growth potential through continuous R&D and global commercialization.”
http://www.economytalk.kr/news/articleView.html?idxno=220019
https://www.wowtv.co.kr/NewsCenter/News/Read?articleId=A202203020120&t=NN
https://sports.chosun.com/news/ntype.htm?id=202203030100010910000526&servicedate=20220302
